CollaGenex Pharmaceuticals, Inc. (CGPI) Seeks Immediate Injunctive Relief To Enforce Its Patent Following Court's Decision Allowing FDA To Approve ANDAs Covering Generic Versions Of Periostat
10/19/2005 5:12:27 PM
NEWTOWN, Pa.--(BUSINESS WIRE)--Jan. 20, 2005--CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced that it intended to seek prompt injunctive relief to protect its patent and intellectual property rights following a decision by the United States District Court for the District of Columbia. The decision upheld the FDA's classification of Periostat(R) as an antibiotic drug which is not entitled to the patent and exclusivity protection otherwise available under the Hatch Waxman amendments to the Food, Drug, and Cosmetic Act. Periostat is the registered trademark of CollaGenex's proprietary 20mg tablets of doxycycline hyclate approved as the only systemic adjunct to scaling and root planing for the treatment of adult periodontitis.
comments powered by